CBC Group

Yisheng Biopharma Co., Ltd., a biopharmaceutical company, researches, develops, manufactures, and markets immuno-oncology products and vaccines. It offers YS-ON-001, an investigational biological product that demonstrates immuno-modulating effects, such as induction of anti-tumor cytokines, activation of NK cells, regulation of macrophage polarization, and suppression of regulatory T cells for the treatment of advanced solid tumors. Yisheng Biopharma Co., Ltd. was founded in 2002 and is based in Beijing with operations in China, the United States, Cambodia, and Singapore.

Adcentrx is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases. By combining the targeting precision of biologics and the disease fighting power of small molecule payloads, Adcentrx strives to develop next generation targeted therapies for improving patient treatment options.

NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

Graybug Vision, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for diseases affecting the retina and optic nerve. Founded in 2011 and based in Redwood City, California, the company is advancing several product candidates, including GB-102, an intravitreal injection formulation currently undergoing Phase I/IIa and IIb clinical trials for wet age-related macular degeneration and Phase IIa trials for diabetic macular edema. Additionally, Graybug is developing GB-103, an annual formulation of GB-102 for diabetic retinopathy, and GB-401, a depot formulation aimed at treating primary open-angle glaucoma. The company's proprietary micro- and nanoparticle controlled release technologies are designed to deliver medications at a sustained rate, enhancing patient compliance and improving clinical outcomes.

I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

NUANCE BIOTECH INC operates as a pharmaceutical development company. The company provides capsules, injections, and tubes. It also engages in research and development for drug development, commercial and academic platform for pharmaceuticals, and contract sales organization services. The company was founded in 2014 and is based in Shanghai, China.

The Chain Medical Labs is a professional independent medical laboratory established from a team of experienced technical and management experts which is one of the Shanghai Chain medical investment management Inc. also alliance with few internationally renowned lab and vendors. The company utilize advanced testing methods, quality management systems, automation technology as Europe, America and Japan for their Clinical Diagnostics. CMLabs features in clinical laboratory services, clinical trial services, research services, and laboratory information system services to support all medical institutions, as well as assist to obtain ISO15189 certification, CAP accreditation (United States Association of pathology quality system), SOP process and external audit services.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

CMAB BioPharm is a Biopharmaceutical Service Firm. Suqiao Bio is a flexible, comprehensive biopharmaceutical custom development and production (CDMO) service company. Strictly in compliance with the quality standards of domestic and international pharmaceutical production management regulations, Suqiao Bio is committed to providing Chinese and global customers with a one-stop shop for preclinical and clinical drug Phase I, Phase II, and Phase III biopharmaceutical products from DNA sequences to commercial production. solution.

I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

Anrei Medical Co., Ltd. is a manufacturer based in Hangzhou, China, specializing in the development, production, and distribution of disposable medical devices designed for minimally invasive procedures. Established in 2006, the company offers a diverse range of products, including stent systems and gastrointestinal tools such as cytology brushes, biopsy forceps, and endoscopy accessories. Additionally, Anrei Medical provides various ERCP accessories and early cancer treatment devices, such as hot biopsy forceps and retrieval nets. Its extensive sales network spans China, North America, Europe, and South Asia, allowing the company to reach a broad market. As a fully owned and FDA-registered enterprise, Anrei Medical is committed to quality and innovation in the medical device sector.

Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, marketing, and sale of pharmaceutical products, primarily in Mainland China and internationally. The company offers several antiviral treatments, including Ganovo for hepatitis C, Pegasys for hepatitis B and C, and Ravidasvir, a pan-genotypic NS5A inhibitor for HCV. Its product pipeline features ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor for non-alcoholic steatohepatitis (NASH) also in Phase II readiness, and ASC41, an oral THR-ß agonist for NASH. Additionally, Ascletis is advancing therapies such as ASC09, a protease inhibitor that has completed Phase IIA trials for HIV, and ASC06, which has finished Phase I trials for liver cancer. The company is also exploring treatments in pre-clinical stages for hepatitis B and NASH. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to create a sustainable business model through innovative drug development and commercialization strategies tailored to the growing Chinese pharmaceutical market.

I-Mab HK develops drugs to treat diabetes, cancer, and autoimmune diseases. The company develops preclinical compounds, including GX-P2; a long-acting PD-L1 drug for the treatment of inflammatory bowel diseases and GX-G8; a long-acting GLP-2 drug for the treatment of chemotherapy-induced diarrhea and short bowel syndrome. The company was formerly known as Tianzhenshi Biotechnology Company and changed its name to I-Mab HK in March 2017. The company is headquartered in Tianjin, China.

FitSAMO is an orthopaedic surgical equipment supplier.

Ascletis Pharma Inc. is a biotechnology company focused on the research, development, manufacture, marketing, and sale of pharmaceutical products, primarily in Mainland China and internationally. The company offers several antiviral treatments, including Ganovo for hepatitis C, Pegasys for hepatitis B and C, and Ravidasvir, a pan-genotypic NS5A inhibitor for HCV. Its product pipeline features ASC22, a PD-L1 antibody fragment in Phase II trials for chronic hepatitis B, ASC40, a fatty acid synthase inhibitor for non-alcoholic steatohepatitis (NASH) also in Phase II readiness, and ASC41, an oral THR-ß agonist for NASH. Additionally, Ascletis is advancing therapies such as ASC09, a protease inhibitor that has completed Phase IIA trials for HIV, and ASC06, which has finished Phase I trials for liver cancer. The company is also exploring treatments in pre-clinical stages for hepatitis B and NASH. Founded in 2014 and headquartered in Hangzhou, China, Ascletis aims to create a sustainable business model through innovative drug development and commercialization strategies tailored to the growing Chinese pharmaceutical market.

FitSAMO is an orthopaedic surgical equipment supplier.

Clarus Therapeutics, Inc. operates as a men's health specialty pharmaceutical company that focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. Clarus Therapeutics, Inc. was founded in 2003 and is based in Northbrook, Illinois.